SKB BIO (06990) rose more than 5% in morning trading. At the time of writing, the stock was up 4.71% to HK$444.2, with a turnover of HK$38.44 million. The move follows an announcement from Merck that its investigational TROP2 antibody-drug conjugate sac-TMT, licensed from SKB BIO, has successfully met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in the Phase 3 TroFuse-005 study for patients with certain advanced or recurrent endometrial cancer. The therapy also delivered positive results on the key secondary endpoint of objective response rate (ORR).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments